GLG News by Addiction Medicine Psychiatrists (US)

1. LY2140023 is an antipsychotic agent that is a metabotropic glutamate 2/3 receptor agonist. This agent has a new mechanism of action that is efficacious in treating schizophrenia and potentially other neuropsychiatric conditions. 2. LY2140023 in addition to separating from placebo in a statistically...

Many pharmaceutical companies tout their "advances", but few of these are totally novel compared to what is currently available.  The recently published trial of LY2140023 for the treatment of schizophrenia is truly inovative and has considerable potential to advance the treatment of schizophrenia...

1. The Actelion agent (ACT-078573) is not a sedative-hypnotic but is an orexin receptor antagonist. 2. This agent may have a safety and tolerability profile that is better than the sedative-hypnotics. 3. The above implications would make Actelion a prime acquisition for a big-pharma company with a less...

1. A recent psychiatric journal reported a higher incidence of bipolar disorders in the pediatric population and a subsequent increase in antipsychotic medication use in children. 2. Assessment tools (bipolar disorder questionnaires) have significantly increased awareness of bipolar disorder symptomatology...

I am a psychiatrist in private practice in a major metropolitan area that has a diverse population. I offer the following observations based on my clinical post-marketing experience. I have already prescribed Vyvanse to a few hundred patients. My observations: 1. Duration of action: This is a huge issue....

1. This agent despite a favorable side effect profile lacks efficacy as compared to other antipsychotic agents already approved by the FDA. 2. This is a temporary setback for Wyeth. 3. This in the long run is to Wyeth's advantage as such an agent would have done poorly in a competitive atypical antipsychotic...

The notion behind this drug (DOV 21,947) is that if you inhibit the reuptake of not only serotonin, not only serotonin and norepinephrine, but also dopamine you are in for a real TRIP (stands for triple receptor uptake inhibitor), presumably better depression treatment, and as a bonus, weight ...

1. Most currently marketed oral antidepressants replenish only norepinephrine or serotonin and result in remission in less than 45% of patients over 8 weeks. A triple reuptake inhibitor such as DOV 21,947 has the potential to effect a remission in a higher percentage of patients. 2. Most of the...

1. An antipsychotic with a novel mechanism of action is highly desirable as currently available atypical antipsychotic agents lack efficacy or cause undesirable side effects (metabolic, extrapyramidal, increased prolactin.) 2. If this agent demonstrated significant efficacy and safety it could be a...

Painkillers are not the problem; the problem is the people who prescribe them and those who take them.  The biggest problem is that the medical profession was encouraged (look at the old advertisements if you have the time) to prescribe slow-release oral formulations of opioids for CHRONIC...